About the Company
Patented EMG (electromyography) control software continuously monitors and senses, but does not stimulate, the affected muscles. The user self initiates and achieves natural movement patterns by their own muscular signals that indicate intention to move. The system senses even a very weak EMG muscle signal and then processes data to a motor on the device that enables desired motion. This processing occurs so quickly that it is not apparent to the patient. Importantly, the EMG-driven device requires that users are actively engaged throughout the movement; if they stop, the device stops. No electrical stimulation or invasive procedures are employed.
By supporting the research into Myoelectric technology in 1990†, the Veterans Administration promoted and inspired development for a future myoelectric orthosis that could be of benefit to Veterans that have upper extremity impairment. Today, Myomo is assisting Veterans with MyoPro.
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo®, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the launch of its Center of Excellence (CoE) program, which recognizes top orthotics and prosthetics (“O&P”) practices in the...
Peer-reviewed Results Indicate Significant Reduction in Upper Extremity Impairment with MyoPro®, with Changes Exceeding Clinically Important Thresholds June 27, 2017 11:55 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Myomo, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage...
Myomo, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that its Chairman and CEO, Paul R. Gudonis, will ring today’s closing bell at the New York Stock Exchange (NYSE) MKT in...